CMTM5 is reduced in prostate cancer and inhibits cancer cell growth in vitro and in vivo

Xiao, Yu; Yuan, Yeqing; Zhang, Y.; Li, J.; Liu, Z.; Zhang, X.; Sheng, Zhiqiang; Xu, Tao; Wang, X.

doi:10.1007/s12094-014-1253-z

Cited by 29 publications

(43 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The growth of ACHN-CMTM5 cells was significantly inhibited, and the cell apoptotic rate was markedly increased, following the transfection of the CMTM5 vector. In addition, it was observed that the restoration of CMTM5 expression suppressed both the motility and invasiveness of ACHN cells, which is in line with previous findings in other tumors (6,7,10,11). In the present study, the ACHN line was selected for functional studies as the CMTM5 mRNA expression level was the lowest of the cell lines tested.…”

Section: Discussionsupporting

confidence: 89%

“…However, similarly to the case of CMTM3, no promoter methylation of CMTM5 was observed in RCC cell lines (16). It has been previously indicated that the expression of CMTM5 in multiple other types of tumor was downregulated in RCC mainly by different epigenetic or genetic mechanisms (6–11). …”

Section: Discussionmentioning

confidence: 99%

“…CKLF-like MARVEL transmembrane domain-containing 5 (CMTM5) is a member of the CMTM protein family and was originally reported by the Human Genomics Center of Peking University (Beijing, China) in 2003 (5). CMTM5 is located at 14q11.2, and has been reported to act as a tumor-suppressor gene (TSG), since it was specifically downregulated in numerous human cancers, including cervical carcinoma, ovarian cancer, pancreatic cancer, myeloid leukemia and prostate cancer (6–11). However, the role of CMTM5 in human RCC remains unclear.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

CMTM5 inhibits renal cancer cell growth through inducing cell-cycle arrest and apoptosis

Cai

Xiao

et al. 2017

Oncology Letters

View full text Add to dashboard Cite

CKLF-like MARVEL transmembrane domain-containing 5 (CMTM5) has been reported to function as a potential tumor suppressor in several human cancers. However, the involvement of CMTM5 in human renal cell carcinoma (RCC) remains unclear. The current study aimed to detect its expression pattern in RCC tissues and cells, and to determine its anti-proliferative functions in this malignancy. The mRNA and protein expression levels of CMTM5 in RCC tissues and cells were detected by reverse transcription-quantitative polymerase chain reaction, immunohistochemistry and western blotting. Following the transfection with CMTM5 lentivirus or control lenti-EGFP lentivirus into the RCC cell line ACHN, the viability, migration, apoptosis and cell cycle of these cells were detected by Cell Counting kit-8 assay, Transwell assay and flow cytometry, respectively. Compared with the adjacent non-malignant kidney tissue samples, CMTM5 expression was significantly downregulated in RCC tissues (P<0.05). In addition, enforced expression of CMTM5 could efficiently inhibit the cell growth of ACHN cells, which were arrested in G0/G1 phase. Furthermore, the migration and invasion of ACHN cells were also inhibited by restoration of CMTM5 expression. The present data suggest that CMTM5 may function as a tumor suppressor in human RCC by suppressing the viability of RCC cells, implying its potential as a therapeutic target for this malignancy.

show abstract

Section: Discussionsupporting

confidence: 89%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

CMTM5 inhibits renal cancer cell growth through inducing cell-cycle arrest and apoptosis

Cai

Xiao

et al. 2017

Oncology Letters

View full text Add to dashboard Cite

show abstract

“…It includes at least six mRNA splicing bodies, CMTM5-v1-v6, of which CMTM5-v1 is the most conserved. CMTM5 is widely expressed in many normal tissues such as brain, prostate and small intestine, and has a secretory form [51], although its expression is greatly reduced in many tumor tissues, such as prostate cancer, cervical cancer, ovarian cancer, leukemia, glioma, and digestive system tumors [52][53][54][55][56]. Its anti-cancer mechanism are not clear, but may be related to promoter methylation or the function of multiple signal transduction pathways [11].…”

Section: Cmtm5 and Nsclcmentioning

confidence: 99%

Research Advances in CKLF-like MARVEL Transmembrane Domain-containing Family in Non-small Cell Lung Cancer

Gu³

et al. 2019

Int. J. Biol. Sci.

View full text Add to dashboard Cite

CKLF-like MARVEL transmembrane domain-containing member (CMTM) is a new gene family first cloned and reported in 2001. The CMTM family consists of nine members including CKLF and CMTM1-CMTM8, which are located on different chromosomes. Besides exhibiting extensive chemotactic activity, the CMTM family plays an important role in the hematopoiesis system, the immune system, the cardiovascular system and the male reproductive system. Recent in-depth research has also revealed that CMTM is closely associated with the genesis, development and metastasis of tumors, displaying opposing activities in diverse human tumors. In this review, we discuss the structural and functional characteristics of the CMTM family and summarize latest research findings of the relationship between several CMTM members and non-small cell lung cancer.

show abstract

“…Once palpable tumors were formed, tumor growth was monitored as described [14]. There were six mice in the Mock group and six in the CMTM3 group.…”

Section: Tumor Xenograft Model In Nude Micementioning

confidence: 99%

CMTM3 is reduced in prostate cancer and inhibits migration, invasion and growth of LNCaP cells

Yuan

Wang

et al. 2015

Clin Transl Oncol

Self Cite

View full text Add to dashboard Cite

We found CMTM3 was reduced in PCa tissues and cells compared with BPH tissues, and its expression in PCa tissues was related to the Gleason score. Moreover, after being transfected with adenovirus, ectopic expression of CMTM3 in LNCaP cells led to significant inhibition of cell proliferation and migration and invasion compared with the control (P < 0.05), which may be attributed to decreased Erk1/2 activity as p-Erk1/2 was remarkably reduced when CMTM3 was overexpressed. Finally, restoration of CMTM3 significantly suppressed xenograft tumor growth in vivo (P < 0.01).

show abstract

CMTM5 is reduced in prostate cancer and inhibits cancer cell growth in vitro and in vivo

Abstract: These results indicate that CMTM5 is down-regulated in PCa and exhibit tumor suppressor activities in androgen-independent PCa cells. Loss of CMTM5 protein may be contributed to the development of PCa and it is a potential therapeutic target for castration-resistant prostate cancer.

Cited by 29 publications

References 30 publications

CMTM5 inhibits renal cancer cell growth through inducing cell-cycle arrest and apoptosis

CMTM5 inhibits renal cancer cell growth through inducing cell-cycle arrest and apoptosis

Research Advances in CKLF-like MARVEL Transmembrane Domain-containing Family in Non-small Cell Lung Cancer

CMTM3 is reduced in prostate cancer and inhibits migration, invasion and growth of LNCaP cells

Contact Info

Product

Resources

About